Commentary: Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer

Front Oncol. 2020 Jan 10:9:1490. doi: 10.3389/fonc.2019.01490. eCollection 2019.

Authors

Giselle V Ripoll^{1

2}, Marina Pifano¹, Juan Garona^{1

2}, Daniel F Alonso^{1

2}

Affiliations

¹ Laboratory of Molecular Oncology, Department of Science and Technology, National University of Quilmes, Bernal, Argentina.
² Scientific Investigator Career of National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina.

No abstract available

Keywords: desmopressin; drug repurposing; hormone-resistant cancer; relcovaptan; vasopressin.

Publication types

Comment